Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells

Life Sciences

Volumn 78, Issue 19, 2006, Pages 2249-2254

  Hagiwara, Hiromi ^a,b   Sato, Hiromi ^a,c   Shirai, Sumiko ^a,d   Kobayashi, Shigeto ^a,d   Fukumoto, Keiko ^a   Ishida, Tatsuya ^a   Seki, Taiichiro ^d   Ariga, Toyohiko ^d   Yano, Tomohiro ^a  

^a NATIONAL INSTITUTE OF HEALTH AND NUTRITION   (Japan)

^b Japan Health Sciences Foundation   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d NIHON UNIVERSITY   (Japan)

Author keywords

Connexin 32; Fibrinolytic factors; Hypoxia inducible factor; Metastatic renal cell carcinoma

Indexed keywords

CONNEXIN 32; FIBRINOLYTIC AGENT; HYPOXIA INDUCIBLE FACTOR 1; MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GENE INDUCTION; HEREDITY; HUMAN; HUMAN CELL; HYPOXIA; KIDNEY CARCINOMA; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CARCINOMA, RENAL CELL; CELL HYPOXIA; CELL LINE, TUMOR; CLONING, MOLECULAR; CONNEXINS; DOWN-REGULATION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; KIDNEY NEOPLASMS; NEOPLASM METASTASIS; PLASMINOGEN ACTIVATOR INHIBITOR 1; RECEPTORS, CELL SURFACE; URINARY PLASMINOGEN ACTIVATOR;

EID: 33645241296     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2005.09.036     Document Type: Article

References (36)

1. P.A. Andreasen, L. Kjoller, L. Christensen, and M.J. Duffy The urokinase-type plasminogen activator system in cancer metastasis: a review International Journal of Cancer 72 1 1997 1 22
2. P.A. Andreasen, R. Egelund, and H.H. Petersen The plasminogen activation system in tumor growth, invasion, and metastasis Cellular and Molecular Life Sciences 57 1 2000 25 40
3. F. Blasi, J.D. Vassalli, and K. Dano Urokinase-type plasminogen activator: proenzyme, receptor, and inhibitors Journal of Cell Biology 104 4 1987 801 804
4. J.K. Chipman, A. Mally, and G.O. Edwards Disruption of gap junctions in toxicity and carcinogenicity Toxicological Sciences 71 2 2003 146 153
5. M.J. Duffy, and C. Duggan The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer Clinical Biochemistry 37 7 2004 541 548
6. V. Ellis, N. Behrendt, and K. Dano Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor Journal of Biological Chemistry 266 19 1991 12752 12758
7. L.M. Ellis, C.A. Staley, W. Liu, R.Y. Fleming, N.U. Parikh, C.D. Bucana, and G.E. Gallick Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src Journal of Biological Chemistry 273 2 1998 1052 1057
8. W.H. Evans, and P.E. Martin Gap junctions: structure and function Molecular Membrane Biology 19 2 2002 121 136
9. M.C. Frame Src in cancer: deregulation and consequences for cell behavior Biochimica et Biophysica Acta 1602 2 2002 114 130
10. E. Fujimoto, H. Sato, S. Shirai, Y. Nagashima, K. Fukumoto, H. Hagiwara, E. Negishi, K. Ueno, Y. Omori, H. Yamasaki, K. Hagiwara, and T. Yano Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line Oncogene 24 22 2005 3684 3690
11. A. Hirai, T. Yano, K. Nishikawa, K. Suzuki, R. Asano, H. Satoh, K. Hagiwara, and H. Yamasaki Down-regulation of connexin 32 gene expression through DNA methylation in a human renal cell carcinoma cell American Journal of Nephrology 23 3 2003 172 177
12. M. Hockel, and P. Vaupel Biological consequences of tumor hypoxia Seminars in Oncology 28 2 Suppl 8 2001 36 41
13. D.W. Hsu, J.T. Efird, and E.T. Hedley-Whyte Prognostic role of urokinase-type plasminogen activator in human gliomas American Journal of Pathology 147 1 1995 114 123
14. B.H. Jiang, F. Agani, A. Passaniti, and G.L. Semenza V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression Cancer Research 57 23 1997 5328 5335
15. M. Krieg, R. Haas, H. Brauch, T. Acker, I. Flamme, and K.H. Plate Up-regulation of hypoxia-inducible factors HIF-1α and HIF-2α under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function Oncogene 19 48 2000 5435 5443
16. B. Krishnamachary, S. Berg-Dixon, B. Kelly, F. Agani, D. Feldser, G. Ferreira, N. Iyer, J. LaRusch, B. Pak, P. Taghavi, and G.L. Semenza Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1 Cancer Research 63 5 2003 1138 1143
17. N.M. Kumar, and N.B. Gilula The gap junction communication channel Cell 84 3 1996 381 388
18. A.P. Mazar, J. Henkin, and R.H. Goldfarb The urokinase plasminogen activator system in cancer: implications for tumor angiogenesis and metastasis Angiogenesis 3 1 1999 15 32
19. G.A. McMahon, E. Petitclerc, S. Stefansson, E. Smith, M.K. Wong, R.J. Westrick, D. Ginsburg, P.C. Brooks, and D.A. Lawrence Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis Journal of Biological Chemistry 276 36 2001 33964 33968
20. M. Mesnil Connexins and cancer Biology of the Cell 94 7-8 2002 493 500
21. H. Miyake, I. Hara, K. Yamanaka, S. Arakawa, and S. Kamidono Elevation of urokinase-type plasminogen activator and its receptor densities as new predictors of disease progression and prognosis in men with prostate cancer International Journal of Oncology 14 3 1999 535 541
22. R.J. Motzer, N.H. Bander, and D.M. Nanus Renal-cell carcinoma New England Journal of Medicine 335 12 1996 865 875
23. K. Ohba, Y. Miyata, S. Kanda, S. Koga, T. Hayashi, and H. Kanetake Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis Journal of Urology 174 2 2005 461 465
24. D.L. Paul New functions for gap junctions Current Opinion in Cell Biology 7 5 1995 665 672
25. G.L. Semenza Hypoxia-inducible factor 1 and the molecular physiology of oxygen homeostasis Journal of Laboratory and Clinical Medicine 131 3 1998 207 214
26. H.M. Sowter, R.R. Raval, J.W. Moore, P.J. Ratcliffe, and A.L. Harris Predominant role of hypoxia-inducible transcription factor (Hif)-1α versus Hif-2α in regulation of the transcriptional response to hypoxia Cancer Research 63 19 2003 6130 6134
27. R. Swiercz, J.D. Wolfe, A. Zaher, and J. Jankun Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype Clinical Cancer Research 4 4 1998 869 877
28. L. Tacchini, E. Matteucci, C. De Ponti, and M.A. Desiderio Hepatocyte growth factor signaling regulates transactivation of genes belonging to the plasminogen activation system via hypoxia inducible factor-1 Experimental Cell Research 290 2 2003 391 401
29. P.M. Termuhlen, S.A. Curley, M.S. Talamonti, M.H. Saboorian, and G.E. Gallick Site-specific differences in pp60c-src activity in human colorectal metastases Journal of Surgical Research 54 4 1993 293 298
30. J.E. Trosko, and R.J. Ruch Cell-cell communication in carcinogenesis Frontiers in Bioscience 3 1998 208 236
31. R.H. Wenger, and M. Gassmann Oxygen(es) and the hypoxia-inducible factor-1 Biological Chemistry 378 7 1997 609 616
32. K. Willecke, J. Eiberger, J. Degen, D. Eckardt, A. Romualdi, M. Guldenagel, U. Deutsch, and G. Sohl Structural and functional diversity of connexin genes in the mouse and human genome Biological Chemistry 383 5 2002 725 737
33. J.L Yang, D. Seetoo, Y. Wang, M. Ranson, C.R. Berney, J.M. Ham, P.J. Russell, and P.J. Crowe Urokinase-type plasminogen activator and its receptor in colorectal cancer: independent prognostic factors of metastasis and cancer-specific survival and potential therapeutic targets International Journal of Cancer 89 5 2000 431 439
34. T. Yano, G. Zissel, J. Muller-Qernheim, S. Jae Shin, H. Satoh, and T. Ichikawa Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3 FEBS Letters 518 1-3 2002 154 158
35. T. Yano, F. Ito, H. Satoh, K. Hagiwara, H. Nakazawa, H. Toma, and H. Yamasaki Tumor-suppressive effect of connexin 32 in renal cell carcinoma from maintenance hemodialysis patients Kidney International 63 1 2003 381
36. Y. Yonezawa, Y. Nagashima, H. Sato, N. Virgona, K. Fukumoto, S. Shirai, H. Hagiwara, T. Seki, T. Ariga, H. Senba, K. Suzuki, R. Asano, K. Hagiwara, and T. Yano Contribution of the Src family of kinases to the appearance of malignant phenotypes in renal cancer cells Molecular Carcinogenesis 43 4 2005 188 197